> 67 Tratamiento sistémico del cáncer de mama BIBLIOGRAFÍA 1. Ayala de la Peña F, Andrés R, García-Sáenz JA, Manso L, Margelí M, Dalmau E, et al. SEOM clinical guidelines in early stage breast cancer (2018). Clin Trasl Oncol. 2019;21:18-30. 2. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288-300. 3. Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017;376:2147-59. 4. Martín M, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, et al. Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. San Antonio Breast Cancer Symposium 2018;Abstract GS2-04. 5. Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, et al. Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2016;34:2416-27. 6. Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28:1700-12. 7. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet. 2019;393:1440-52. 8. Caparica R, Bruzzone M, Poggio F, Ceppi M, de Azambuja E, Lambertini M. Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2019;174:27-37. – Tabla II – Esquemas de tratamiento quimioterápico adyuvante más empleados en cáncer de mama AC x 4 → paclitaxel x 12: - Adriamicina 60 mg/m2 día 1 - Ciclofosfamida 600 mg/m2 día 1, cada 21 días x 4 ciclos seguidos de paclitaxel 80 mg/m2 /semana x 12 ciclos “Dosis densas” AC x 4 → paclitaxel: - Adriamicina 60 mg/m2 día 1 - Ciclofosfamida 600 mg/m2 día 1 cada 14 días x 4 ciclos (con profilaxis primaria con G-CSF) seguidos de paclitaxel 175 mg/m2 cada 14 días x 4 ciclos (con profilaxis primaria con G-CSF) o bien 80 mg/m2 /semana x 12 ciclos (esquema de paclitaxel semanal preferido) AC x 4 → docetaxel x 4: - Adriamicina 60 mg/m2 día 1 - Ciclofosfamida 600 mg/m2 día 1 cada 21 días x 4 ciclos seguidos de docetaxel 100 mg/m2 cada 21 días x 4 ciclos TAC x 6: - Docetaxel 75 mg/m2 día 1 - Adriamicina 50 mg/m2 día 1 - Ciclofosfamida 500 mg/m2 día 1 cada 21 días x 6 ciclos con soporte de G-CSF FEC100 x 3 → docetaxel x 3 - 5-fluorouracilo 500 mg/m2 día 1 - 4-epirrubicina 100 mg/m2 día 1 - Ciclofosfamida 500 mg/m2 día 1 cada 21 días x 3 ciclos seguidos de docetaxel 100 mg/m2 cada 21 días x 3 ciclos FAC con Myocet ® x 4 → paclitaxel x 12: - 5-fluorouracilo 500 mg/m2 día 1 - Myocet ® 50 mg/m2 día 1 - Ciclofosfamida 500 mg/m2 día 1 cada 21 días x 4 ciclos seguidos de paclitaxel 80 mg/m2 /semana x 12 ciclos TC x 4-6: - Docetaxel 75 mg/m2 día 1 - Ciclofosfamida 600 mg/m2 día 1 cada 21 días x 4 o 6 ciclos CMF x 6: - Ciclofosfamida 600 mg/m2 días 1 y 8 - Metotrexate 40 mg/m2 días 1 y 8 - 5-fluorouracilo 600 mg/m2 días 1 y 8 cada 28 días x 6 ciclos
RkJQdWJsaXNoZXIy MTQzMjMwMg==